Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10634236rdf:typepubmed:Citationlld:pubmed
pubmed-article:10634236lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:10634236lifeskim:mentionsumls-concept:C0030567lld:lifeskim
pubmed-article:10634236lifeskim:mentionsumls-concept:C1520007lld:lifeskim
pubmed-article:10634236pubmed:issue1lld:pubmed
pubmed-article:10634236pubmed:dateCreated2000-2-10lld:pubmed
pubmed-article:10634236pubmed:abstractTextParkinson's disease is an obvious target for the development of gene therapy procedures which could involve both the delivery of the gene encoding tyrosine hydroxylase to boost dopamine production or the delivery of genes encoding neurotrophic factors such as GDNF to promote the survival of dopaminergic neurons. A variety of different viral and nonviral methods for achieving such gene delivery are described together with the particular advantages of herpes simplex virus-based vectors which have the potential to deliver multiple therapeutic genes in a single virus vector.lld:pubmed
pubmed-article:10634236pubmed:languageenglld:pubmed
pubmed-article:10634236pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10634236pubmed:citationSubsetIMlld:pubmed
pubmed-article:10634236pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10634236pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10634236pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10634236pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10634236pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10634236pubmed:statusMEDLINElld:pubmed
pubmed-article:10634236pubmed:monthJanlld:pubmed
pubmed-article:10634236pubmed:issn0885-3185lld:pubmed
pubmed-article:10634236pubmed:authorpubmed-author:LatchmanD SDSlld:pubmed
pubmed-article:10634236pubmed:authorpubmed-author:CoffinR SRSlld:pubmed
pubmed-article:10634236pubmed:issnTypePrintlld:pubmed
pubmed-article:10634236pubmed:volume15lld:pubmed
pubmed-article:10634236pubmed:ownerNLMlld:pubmed
pubmed-article:10634236pubmed:authorsCompleteYlld:pubmed
pubmed-article:10634236pubmed:pagination9-17lld:pubmed
pubmed-article:10634236pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10634236pubmed:meshHeadingpubmed-meshheading:10634236...lld:pubmed
pubmed-article:10634236pubmed:meshHeadingpubmed-meshheading:10634236...lld:pubmed
pubmed-article:10634236pubmed:meshHeadingpubmed-meshheading:10634236...lld:pubmed
pubmed-article:10634236pubmed:meshHeadingpubmed-meshheading:10634236...lld:pubmed
pubmed-article:10634236pubmed:meshHeadingpubmed-meshheading:10634236...lld:pubmed
pubmed-article:10634236pubmed:meshHeadingpubmed-meshheading:10634236...lld:pubmed
pubmed-article:10634236pubmed:meshHeadingpubmed-meshheading:10634236...lld:pubmed
pubmed-article:10634236pubmed:meshHeadingpubmed-meshheading:10634236...lld:pubmed
pubmed-article:10634236pubmed:meshHeadingpubmed-meshheading:10634236...lld:pubmed
pubmed-article:10634236pubmed:meshHeadingpubmed-meshheading:10634236...lld:pubmed
pubmed-article:10634236pubmed:meshHeadingpubmed-meshheading:10634236...lld:pubmed
pubmed-article:10634236pubmed:year2000lld:pubmed
pubmed-article:10634236pubmed:articleTitleViral vectors in the treatment of Parkinson's disease.lld:pubmed
pubmed-article:10634236pubmed:affiliationDepartment of Molecular Pathology, Windeyer Institute of Medical Sciences, University College London, UK.lld:pubmed
pubmed-article:10634236pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10634236pubmed:publicationTypeReviewlld:pubmed
pubmed-article:10634236pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed